FRA3B at human chromosomal band 3p14.2 is the most active common fragile site in the human genome. The molecular mechanism of fragility at this region remains unknown but does not involve expansion of a trinucleotide or minisatellite repeat as has been observed for several of the cloned rare fragile sites. Deletions and rearrangements at FRA3B have been observed in a number of distinct tumors. The recently identi®ed putative tumor suppressor gene FHIT spans FRA3B, and various groups have reported identifying deletions in this gene in dierent tumors. Using a high density of PCR ampli®able markers within FRA3B searching for deletions in the FRA3B region, we have analysed 21 tumor cell lines derived from renal cell, pancreatic, and ovarian carcinomas. We found a commonly deleted region in the renal cell and ovarian carcinoma cell lines located in the middle of an HPV16 viral integration site. Despite the presence of deletions in the FRA3B region in most of the cell lines, we did not detect alterations in FHIT exons in any of the cell lines examined. Thus, deletions of 3p14.2 in these carcinoma cell lines may simply re¯ect instability of the FRA3B region during tumor progression.
Introduction
Fragile sites on chromosomes are regions susceptible to breakage when cells are exposed to speci®c experimental conditions. Some chemicals such as inhibitors of the folic acid pathway,¯uorodeoxyuridine, caeine, and aphidicolin, can induce the expression of fragile sites during metaphase. The fragile sites can be classi®ed as common or rare, based upon the frequency of their occurrence in the human population (Sutherland and Hecht, 1985) . Expression of the known cloned rare fragile sites is associated with the expansion of trinucleotide or minisatellite sequences (Fu et al., 1991; Knight et al., 1993; Parrish et al., 1994; Jones et al., 1994; Yu et al., 1997) . Common fragile sites appear to be present in all individuals and most are induced by the DNA polymerase a inhibitor aphidicolin (Glover et al., 1984) . The biological signi®cance of the common fragile sites is that they are localized to chromosomal bands that are frequently rearranged in various types of cancers (Yunis and Soreng, 1984) . However, whether or not fragile sites play a causative role in these structural chromosome alterations has yet to be determined. FRA3B, at chromosome band 3p14.2, is the most highly inducible fragile site in the human genome (Smeets et al., 1986) . The constitutive familial renal cell carcinoma-associated translocation t(3;8)(p14.2;q24) (hRCC) (Cohen et al., 1979) was localized immediately centromeric of FRA3B (Paradee et al., 1995; Boldog et al., 1993) . Structural rearrangements and deletions at FRA3B were reported in a variety of histologically dierent cancers including lung , breast (Panagopoulos et al., 1996) , esophageal , ovarian (Ehlen et al., 1990) , and renal cell carcinoma (RCC) (Druck et al., 1995; van den Berg et al., 1997) .
We previously reported frequent breakage at FRA3B in renal cell carcinoma and pancreatic cancer . Limited polymorphic microsatellite markers in this region and normal cell contamination in tumor tissues restricted our further allelotype analysis in paired tumor tissues. The advantage of working with tumor cell lines is that they are free of normal cell contamination and can thus be used for the analysis of homozygous deletions even with markers that are not polymorphic. We analysed deletions in the FRA3B region using 27 STS markers to delineate the deleted fragments along this region in 21 tumor cell lines (eight RCCs, eight pancreatic, and ®ve ovarian carcinomas). The high density of STS markers allowed us to map small deletions in these tumors. A frequent deletion/breakage region was detected in the center of the FRA3B region, de®ned by FISH analysis in RCCs and ovarian cancers. Unlike the changes that have been reported in some human tumors Sozzi et al., 1996) , the RCCs, pancreatic and ovarian carcinomas had no apparent FHIT gene alterations.
Results
Positions of STS markers, repetitive sequences and restriction sites on the FRA3B cosmid contig
We previously described the isolation of a contig of overlapping cosmid clones which extended distally from the hRCC and covered the majority of the FRA3B region (Paradee et al., 1995) . The landmarks in this region are the hRCC breakpoint (Boldog et al., 1993) , two distinct clusters of aphidicolin-induced breakpoints (one 100 Kb and the other 300 Kb distal to the hRCC) (Paradee et al., 1995) , an HPV16 viral integration site , and a pSV2neo integration site (Rassool et al., 1996) . STS markers were assigned to a particular cosmid based upon PCR ampli®cation against the cosmids in the contig. Of 22 markers between D3S1480 and D3S1300, 19 were positioned in one or more cosmids in the FRA3B contig ( Figure 1a) . With three of the tested markers (D3S4489, spc-F/R, and spc-DNA1), we could not detect positive PCR Figure 1 (a) Map of the telomeric region of YAC 850A6. Included on this map is the cosmid contig across this region and the precise position of the 22 PCR ampli®able markers used to analyse this region. Also included on this ®gure is a partial restriction map for this region, the position of the localized THE-1 elements, and the locations of the hRCC, the proximal and distal aphidicolin-induced breakpoint clusters, the HPV16 viral integration site, and the pSV2neo integration site. The region where aphidicolin-induced decondensation/breakage is detected by FISH analysis begins at the proximal and ends at the distal breakpoint cluster and is indicated above the restriction map. Also included on this map is the relative sizes of each of the various regions. The question mark in the middle of the proximal cluster of breakpoints re¯ects the fact that we are not sure of the precise size of the gap in this region. (b) Map of the region surrounding the HPV16 viral integration site. Shown on this map is the precise position of the 5 PCR ampli®able markers from this region, the HPV16 viral integration sequence, two Alu elements, the (ttttg) 5 microsatellite, and the psCyclophilin pseudogene. Also shown is the commonly deleted region detected in the RCC and ovarian cell lines signals with any of the 14 cosmids. However, based on the published sequence (GenBank Accession Number U66722) for much of this region (Boldog et al., 1997) they were assigned to a gap between cosmids 1A6 and 1C4, and ordered relative to each other. The cosmid 4B4 which linked 1A6 and 1C4 in our previous report was moved to a more distal region on our contig since it shares the pSV2neo integration site, exon 5 of the FHIT gene, and D3S1300 with 3C3. For most cosmids in this contig, we positioned restriction sites along the cosmids and this enabled us to determine relative distances between the various landmarks, the microsatellites, and STSs from this region, especially in areas that were not part of the region that was sequenced by Boldog et al. (1997) . However, only relative positions of selected restriction fragments are presented. Figure 1a does not represent an actual map with precise sizes of all the fragments.
Three repetitive sequence elements (Alu, LINE, and THE) were hybridized to DNA from the 14 cosmids using Southern hybridizations. Unfortunately, the normal density of Alu and LINE sequences along this region made it dicult for us to precisely localize these two kinds of sequences in the cosmid contig by Southern blot analysis. However, the THE element is relatively rare in the human genome (occurring once every 300 Kb in human DNA). Southern blot analysis determined there were three THE elements in the cosmid contig, one in cosmid 1A6 at the proximal end of the FRA3B region and the remaining two at the intersection of cosmids 3F1 and 7A1. Figure 1a shows a map of the cosmid contig and its position relative to YAC YC850A6. Included on this ®gure are the locations of the hRCC translocation breakpoint, the FRA3B region, the restriction map constructed from some of the cosmids in the contig, and the precise position of the various PCR ampli®able markers derived from this region.
Distribution of deletions/breaks in FRA3B
The PCR-ampli®able markers used in this study span the region from D3S1600 (proximal to FRA3B) to D3S1234 (distal to FRA3B). This region extends for about 1 Mb within 3p14.2 and covered the hRCC breakpoint, the proximal and distal cluster of aphidicolin-induced breakpoints, the HPV16 viral integration site, and the two pSV2neo insertions. Deletions at the more proximal markers which included D3S1600, D3S1312, D3S1480, T23-t, 1A6E6 and D3S4260 were infrequently observed (Table 1) . Similarly, deletions at a distal marker (D3S1313) were also infrequently observed. D3S1234, the most distal marker, did not show any deletions in any of the cell lines examined. PCR markers (U39804-1 through -5) came from a 3.5 Kb DNA sequence (accession no. U39804) which covered an HPV16 integration site and seemed to be within the center of the FRA3B region as determined by FISH analysis . These ®ve markers showed a very high frequency of deletions in the RCC and ovarian cancer cell lines (Table 1) . One marker, U39804-5, was deleted in 16 of 21 samples and was homozygously deleted in 8/8 RCC samples, 4/5 ovarian cancers, 1/8 pancreatic cancers, and heterozygously deleted in three of eight pancreatic cancers. This marker covered the distal boundary of the HPV16 viral integration site and an Alu repetitive sequence. Immediately distal to the frequently deleted marker was a perfect (ttttg) 5 microsatellite, an Alu repeat, and a cyclophilin pseudogene ( Figure 1b ). Another frequently deleted marker was D3S4483, which was homozygously deleted in 5/8 pancreatic cancers, 1/5 ovarian cancers, and heterozygously deleted in 4/8 RCCs. To con®rm that these markers were actually homozygously deleted, we performed multiplex PCR using D3S1312. Figure 2 shows the results of this analysis which demonstrated homozygous and apparently hemizygous deletions of marker U39804-3 in the cell lines examined. To make sure that the absence of ampli®cation of these markers, which was scored by us as homozygous deletions, was not caused by insertion/deletion polymorphisms or sequence variations that would prevent priming we analysed 100 normal individuals for ampli®cation of the markers in the HPV16 viral integration site. This analysis revealed that none of the PCR primers detected deletions in the normal individuals demonstrating that the homozygous and heterozygous deletions detected were not the result of sequence polymorphisms in this region.
Number of deletions/breaks in FRA3B region
We scored each of the samples for the number of breakpoints in the FRA3B region. Breakpoints were ascertained between two markers if one marker was present and the immediately adjacent marker was deleted (either homozygously or heterozygously). For example, RCC HTB-44 had 11 breakpoints while HTB-45 only had two breakpoints within the 1 Mb region bordered by D3S1234 and D3S1600 (Table 1) . Of the 21 cell lines examined, 20 showed deletions/ breaks in the region. The RCC sample HTB-46 had the highest number of breakpoints (total 13). Only one cell line (pancreatic cell line CAPAN-1) had no breakpoints in the FRA3B region. Of the 27 markers tested, the marker U39804-5 within the HPV16 integration site had the highest frequency of deletions as well as breakpoints in the region surrounding it. Most of the cell lines had multiple breakpoints in the FRA3B region. In the RCC and ovarian cell lines, these breakpoints were centered on the HPV16 viral integration site. In contrast, the breakpoints in the pancreatic cell lines were more frequently observed either proximal or distal to the HPV16 integration site.
Deletions of the FHIT gene
Recently, the FHIT gene was shown to span the hereditary RCC translocation breakpoint and FRA3B . Using nested RT ± PCR analysis, partial deletions of this gene were shown in a variety of cancer tissues and cancer cell lines (Fong et al., 1997; Druck et al., 1997; Kastury et al., 1996; Panagopoulos et al., 1996; Negrini et al., 1996; Yamagisawa et al., 1996; Mao et al., 1996; Virgilio et al., 1996; Sozzi et al., 1996) . We analysed the FHIT exons using non-nested RT ± PCR in each of the 21 tumor cell lines. A single, prominent RT ± PCR product with no major aberrant transcription products was observed in all the cell lines (data not shown). This clearly indicated that there were no homozygous FHIT exon alterations in any of these tumor cell lines. This can also be clearly seen in Table  1 where we examined LOH for exon 4 and 5 of the FHIT gene. None of the cell lines examined had homozygous deletions in either exon 4 or exon 5 of the FHIT gene, but 4/8 of the RCC cell lines and 1/8 of the pancreatic cell lines had what appeared to be a heterozygous exon-5 deletion and 4/8 of the RCC cell lines had a heterozygous exon-4 deletion. We still found a predominance of full length RT ± PCR FHIT products in all of the cell lines examined. We detected some smaller RT ± PCR products from some of the cell lines, but these were always only present at a very low abundance suggesting that we had selectively ampli®ed infrequent alternatively spliced transcripts. Deletion analysis in the 21 tumor cell lines. Listed across the top are the eight RCC cell lines, the eight pancreatic cell lines, and the ®ve ovarian cell lines. Listed down the side are the 27 PCR ampli®able markers used in the analysis. The markers are listed from the most telomeric marker, D3S1234, to the most centromeric marker, D3S1600. A+ denotes good PCR ampli®cation with a tested marker (scored as allele retention); a black box represents homozygous deletion of a tested marker, and a gray box with a + denotes heterozygous deletion of a tested marker. Shown on the bottom is the number of detectable breakpoints in the region analysed in each of the tumor cell lines. Note that only one cell line, CAPAN-1, had no breakpoints in this region 
Discussion
Chromosome 3p14.2 is the most active of the common fragile sites in the human genome. Frequent deletions/ breaks at 3p14 were reported in a large variety of human cancers including renal cell carcinoma, breast cancer, pancreatic cancer, esophageal cancer, and lung cancer as mentioned above. However, the molecular basis of the genomic instability at this region, either in the presence of aphidicolin or during cancer progression, was not clear. Another important unresolved issue is the precise relationship between FRA3B sequences and chromosomal deletions in 3p14.2 in tumor cells. Most of the previous studies analysing deletions in this region were based on loss of heterozygosity. Since only a few markers from this region were polymorphic, it was impossible to precisely localize the deletion/breakage within and relative to FRA3B.
In previous reports, we found frequent breakpoints in the FRA3B region in primary pancreatic cancer and renal cell carcinoma . These reports demonstrated that many tumors had deletions and multiple breakpoints in the FRA3B region. In this report, we analysed a number of tumor cell lines. The absence of normal cell contamination in these cell lines enabled us to use non-polymorphic STS markers in addition to known microsatellites from this region, and thus we could precisely localize the breakpoints between these markers and position the breakpoints relative to the FRA3B region. The partial restriction map for the FRA3B region and the sequence data for much of the FRA3B region from Boldog et al. (1997) enabled us to know the precise distance between many of the markers and microsatellites used in this study. We found the most common deletion occurred in the HPV16 integration site represented by the markers U39804-1 through 5, especially between U39804-3 and U39804-5; these two markers cover about 0.9 Kb DNA sequences including an HPV16 viral integration site and an Alu sequence. Immediately distal to the common deletion region are a (ttttg) 5 microsatellite sequence and another Alu sequence (Figure 1b) . However, it is not clear if the Alu sequence or the (ttttg) 5 microsatellite play an important role in the frequent deletion within the HPV16 integration site in RCCs and ovarian cancers.
The pancreatic cancer cell lines did not have such a high frequency of homozygous deletions in the HPV16 integration site. Instead, we de®ned a more proximal marker D3S4483 with homozygous deletions. This marker was localized in intron 3 of FHIT gene and was found homozygously deleted in 5/8 pancreatic cancers (Table 1) . Since the deletions in the RCC and ovarian cell lines occurred in the middle of FRA3B in the HPV16 viral integration site, whereas the deletions were found to be more centromeric in the pancreatic cell lines, this may re¯ect dierent sequence fragility in dierent tissues. However, the hypothesis we favor is that tumors which have an HPV16 involvement may show greater instability at the HPV16 viral integration site. HPV infection was reported to be related to the etiology of various human tumors including renal cell (Kamel et al., 1994) and cervical carcinoma (Wagatsuma et al., 1990). However, this is not known for ovarian cancer. We are currently analysing the cell lines for the presence of HPV16 sequences and performing FISH-based analyses to determine where HPV16 resides in those cell lines that contain HPV16 sequences.
The FHIT exons represent about 1.1 Kb of mRNA spread out over 1 Mb of genomic DNA which includes FRA3B and the hRCC (Zimonjic et al., 1997) . The gene is believed to be a potential tumor suppressor gene in a variety of human tumors based upon the observation of aberrant nested RT ± PCR products Virgilio et al., 1996; Sozzi et al., 1996) . However, the biological function of FHIT is still unclear in tumor progression. Fong et al. (1997) found that FHIT gene/FRA3B allele loss was common in lung cancer and associated with cancer-related cDNA splicing aberrations. The simultaneous presence and relative abundance of wild type transcripts as well as aberrant transcripts in several tumor and even normal samples (Fong et al., 1997; Boldog et al., 1997) implies that FHIT is dierent from most other known tumor suppressor genes. Since the gene spans the most active common fragile site, the alteration of the gene in human tumors may only re¯ect the fragility of FRA3B. Consistent with this data, the RT ± PCR products from our 21 tumor cell lines showed normal size with only a few faint aberrant PCR products detectable. This supports the contention that the FHIT gene is not involved in the progression of RCC and ovarian cancer (Bugert et al., 1997; Hendricks et al., 1997) . We did ®nd some smaller RT ± PCR products in the pancreatic carcinoma cell lines (data not shown) but the majority of the products were still the normal size. The LOH data with the markers analysed also support the contention that FHIT is not a target of mutations, at least in the cell lines examined. Whereas 19 of 21 cell lines had homozygous deletions of at least one of the tested markers, none of the cell lines had homozygous deletions of either exon 4 or exon 5 of FHIT. Allele loss was detected in ®ve cell lines at exon 5 and in four cell lines at exon 4 but the dramatic loss of sequences throughout the rest of the region raises the possibility that selection has resulted in speci®c retention of FHIT exons in several of the cell lines. Our results demonstrating homozygous deletions in this region that only involve sequences in the FHIT introns are similar to results reported by Boldog et al. (1997) and van den Berg et al. (1997) .
An important question is why we did not detect smaller FHIT RT ± PCR products in the cell lines with heterozygous deletions in FHIT exons. A similar observation was made by Druck et al. (1997) . They found that cell line HKI was deleted for exon 5 by PCR analysis and RT ± PCR failed to detect any FHIT transcript. Thus, the deletion of that exon might cause the cell to rapidly degrade the smaller aberrant transcript. In cell lines that we examined with heterozygous FHIT exon deletions the smaller FHIT transcripts might be degraded leaving only intact FHIT transcripts to be ampli®ed by RT ± PCR. Samples were scored as having heterozygous deletions based on showing 5 ± 50% of the expected signal. However, several of the markers had ampli®cation that was signi®cantly less than 50%. This would imply that the tumor cell lines were heterogeneous for loss of FHIT exon or intron markers. This was also similar to results reported by Druck et al. (1997) .
The FHIT gene has been proven to have huge intronic sequences (especially introns 4 and 5) which could be the potential location of many other genes. We have identi®ed homozygous/heterozygous deletions within intron 4 in all eight RCC cell lines, seven of eight pancreatic cell lines, and all ®ve ovarian cancer cell lines, including discontinuous deletions in at least 16 cell lines. There may, therefore, be another gene within FHIT intron 4 which is the actual target in these cancers. Alternatively, this may only re¯ect the genomic instability in the FRA3B region.
A number of studies have shown a statistical association between the integration of transforming DNA viruses and chromosomal fragile sites (Popescu et al., 1990) . Smith et al. (1992) reported that HPV integration sites were consistent with integration near or within known fragile sites in ®ve of six HPVimmortalized keratinocyte cell lines. Wilke et al. (1996) have shown that a region of frequent breakage within FRA3B coincided with a previously characterized site of HPV16 integration in a primary cervical carcinoma. Frequent deletions in the HPV16 integration site in the RCC and ovarian cell lines suggest that this viral integration site in the human genome may be particularly unstable. However, whether these tumor cell lines have HPV infection and whether the frequent deletions in FRA3B are caused by an HPV16 integration remain unclear.
Repetitive sequences such as THE-1, LINE, and Alu may be responsible for rearrangements and deletions in many human diseases and cancers (Reiter et al., 1996; Mauillon et al., 1996; Puget et al., 1997) . The repetitive elements could cause misalignment during meiosis and mitosis through the formation of loop structures of the inverted repeats. In an attempt to map these repeat sequences in the FRA3B contig, we hybridized the digested cosmid DNA with the labeled repetitive sequences. As the human genome is rich in LINE and Alu sequences, numerous positive signals were observed in all of the cosmids (data not shown). The Alu repeats tend to distribute on the proximal part of the contig including 6H8, 1C12, and 1C6 while LINEs more heavily distribute on the distal part of the contig including 1C4, 3F1, 1D10, 3C3, 4B4, and 3C8 (data not shown). The THE1 sequence is sparsely distributed throughout the human genome, occurring once every 300 Kb. We found three positive signals in cosmid 1A6, 3F1 and 7A1, respectively. One THE1 element was localized in the aphidicolin-induced proximal breakpoint cluster ; the other two were positioned just distal to cosmid c55 which is believed to be the center of the FRA3B region (Paradee et al., 1995) . Thus, these three THE1 elements were located within a 150 Kb region. The relative abundance of THE1 elements in FRA3B may be one of the factors that contribute to the fragility at this fragile site.
Small polydispersed circular DNA (spcDNA) was suggested to be associated with genetically unstable cells (Cohen et al., 1997) . Boldog et al. (1997) reported sequences with signi®cant similarity to spcDNA in a 600 bp region at the centromeric end of the 110 Kb of FRA3B sequences that they generated (GenBank Accession Number U66722). The marker spcDNA1, which was 4 Kb telomeric to the spcDNA homologous sequences, was found deleted in 12/21 tumor samples including 5/5 deletions in ovarian cancers (Table 1) . In contrast, the marker spc-F/R, which is within the spcDNA homologous sequence, did not show any deletion in all 21 tumor samples. Thus it seems that in the cell lines examined the spcDNA sequences are not playing a role in the deletions in this region.
In summary, we have mapped the STS markers on the FRA3B cosmid contig. Deletion mapping in 21 tumor cell lines showed that frequent deletion/breaks occur within the HPV16 viral integration site. The frequent homozygous and heterozygous deletion in 3p14.2 may only re¯ect the fragility of the FRA3B region during tumor progression rather than deletions in an important tumor suppressor gene from this region.
Materials and methods

Tumor cell lines and cell culture
Eight renal cell carcinoma cell lines (HTB-44, HTB-45, HTB-46, HTB-47, HTB-49, CRL-1611 , CRL-1932 and CRL-1933 and eight pancreatic cell lines (CFPAC, SU-86, BXPC-3, ASPC-1, MIA, CAPAN-1, CAPAN-2 and HS-766T) were obtained from ATCC. The ®ve ovarian cancer cell lines were from the Mayo Foundation. Cell culture was performed based on conditions described by ATCC (for the RCC and pancreatic cell lines) or conditions described in Jenkins et al. (1993) for the ovarian cell lines.
DNA, RNA extraction and reverse transcription
Cells were grown to con¯uency on¯asks and were then washed twice in PBS and submerged in DNA extraction buer (10 mM Tris, 1 mM EDTA, 100 mM NaCl, 0.05% SDS and 100 mg/ml proteinase K) for 10 min. The mixed solutions were then transferred to test tubes for further digestion overnight at 378C. After standard phenol/chloroform extraction, the DNA was precipitated in ethanol, dried, and redissolved in TE buer.
Total RNA was extracted from these cell lines using Trizol reagent (Life Technologies, Inc.) according to the manufacturer's instructions. Reverse transcription was performed in a 20 ml ®nal volume containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 0.125 mM each dNTP, 0.5 mg of oligo-dT, 2.5 mM hexamer, 200 units of Superscript II reverse transcriptase (Life Technologies, Inc.), 20 units of RNase inhibitor (Boehringer Mannheim), and 1 mg of total RNA. The reaction was incubated at 388C for 90 min and 958C for 5 min.
STS markers for deletion mapping of genomic DNA
A total of 27 STS markers within 3p14.2/FRA3B were selected to map potential deletions in this region. Microsatellite PCR primers (D3S1234, D3S1313, D3S2977, D3S1300, D3S4482, D3S4474, D3S2757, D3S4480, D3S4483, D3S4489, D3S4260, D3S1480, D3S1312 and D3S1600) were obtained from Research Genetics or synthesized based on the Genome Database. Primers FHIT-EX5, FHIT-EX,4 and U39799 came from a published paper on the structure of the FHIT gene, and the conditions for their ampli®cation were exactly as described in the paper . Other primers constructed are listed below (5' to 3'): U39804-1F/R: CTGGCCTTATCATTCCTG / TCCAGGGTGGTGACTT-CA (588C) U39804-2F/R: GCCACTAGGAATTCAGG-CA/ATCTGTCAGCTCACTGGCCT (618C) U39804-3F/ R : AGGGTTAATCAACCAATCCA/TTTGCTATGTGA -TGAGGCTG (588C) U39804-4F/R:TGTGCTAGCAT-GCATTCCTC/AAGGCGCCATGTTATAATGC (568C) U39804-5F/R:TAGAGTTGGCATGAGAGCTG /TGTTG-GTATCACTGCACTCC (588C) C5EX-F/R:CCTGGA-TGAATCCTTCTTGG/ACGTGTGAATGAGGCAGAGA (588C) spc-DNA1F/R : TGTCAATGCTGCACTAAGGC/ GGGAGAGAATCAGAGGAGCC (588C) spc-F/R:GAC-TTCCTTCTGTCCCAT/ATATAATCCCTGTGGTAACT (588C) 1A6E6-F/R : ATCTGATGGGTTTATCAGGG / C-ATGTTACCCAGCCTGGTCT (598C) T23-t F/R:GGC-TAAGAGATCAAGAGTG /GGACTCCATCATACCGTT (608C).
Primers for FHIT gene RT ± PCR (608C reannealing temperature), were: FHIT-231(F): AAGGGAGAGAAAGA-GAAAGAAG; FHIT-954(R): TCACTGGTTGAAGAATA-CAGGA.
PCR ampli®cation
PCR was performed in a DNA Thermal Cycler 480 (Perkin Elmer Cetus). The reactions consisted of 100 ng genomic DNA (or 1 ml RT product), 6.25 pmol of each forward and reverse primer, 100 mM of each dNTP, 1.5 mM MgCl 2 , 16Taq DNA polymerase buer and 0.5 unit of Taq DNA polymerase (Promega). The ampli®cation mixtures (12.5 ml) were denatured at 948C for 3 min and then subjected to 35 cycles of 948C for 20 s, 55 ± 628C for 30 s (the precise reannealing temperature for each primer pair is listed above after the sequence of each primer pair) and 728C for 30 ± 60 s.
Determination of homozygous and heterozygous deletions
All PCRs were performed at least twice; inconsistent PCR results were repeated one more time. Only completely negative signals were counted as homozygous deletions. All gels were analysed on the Gel-Doc 1000 gel documentation system (Bio-Rad). PCR reactions that consistently yielded less than 5% of the expected signal were scored as homozygous deletions. In most instances, markers scored as being homozygously deleted showed absolutely no PCR product with the tested marker. Markers that yielded between 5 ± 50% of the expected signal were scored as heterozygously deleted. Markers that were suspected to be homozygously or heterozygously deleted were con®rmed using multiplex PCR with another primer pair that was not deleted. The comparative primer pairs were chosen based upon the similarity between their reannealing temperature and that of the primer pair being tested, and also analysed to be sure that no potential pairing was possible between the dierent primer sets that were multiplexed. All the gels from the multiplex analysis were also analysed and quantitated on the Gel-Doc 1000 gel documentation system and similarly scored.
Mapping of STS markers in the FRA3B cosmid contig
Single colonies of each of the 14 cosmids in the FRA3B cosmid contig were selected for mapping of STS markers in this region. The cosmid DNA was extracted by using the QIAGEN-DNA Extraction Kit. PCR ampli®cation was performed as described above except that we used 1 pg of cosmid DNA, as compared to 100 ng genomic DNA. The position of each STS marker relative to the cosmid contig was determined according to a positive or negative signal with a particular cosmid.
Southern blot analysis of repetitive sequences
Cosmid DNAs in FRA3B cosmid contig were digested using restriction enzymes (HindIII and PstI) and subjected to electrophoresis in 0.8% agarose gels. The digested cosmid DNAs were transferred onto Hybond-N (Amersham) membranes and hybridized with probes (human ALU, LINE and THE1 repetitive sequences) labeled with 32 P-dCTP using random hexamer primers.
Restriction map of the FRA3B cosmid contig
Four restriction enzymes (XhoI, SalI, S®I and SacII) were used for restriction mapping of this contig. The digested DNAs were run on a 0.5% agarose gel and analysed. The restriction site was positioned according to the relative size of the fragmented DNA using dierent enzyme combinations.
